Verona Pharma (VRNA) News Today $35.66 +0.29 (+0.82%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period 29,513 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by GSA Capital Partners LLPGSA Capital Partners LLP purchased a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 29,513 shares of the company's stock, valued at approximaNovember 17 at 3:52 AM | marketbeat.com16,150 Shares in Verona Pharma plc (NASDAQ:VRNA) Purchased by Crossmark Global Holdings Inc.Crossmark Global Holdings Inc. acquired a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,150 shares of the company's stock, valuedNovember 17 at 3:25 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 2,400 SharesNovember 14 at 9:14 AM | insidertrades.comTruist Financial Issues a Buy Rating on Verona Pharma (VRNA)November 13, 2024 | markets.businessinsider.comVerona Pharma (NASDAQ:VRNA) Reaches New 52-Week High - Here's What HappenedVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High - Time to Buy?November 11, 2024 | marketbeat.comCaligan picks up a stake in Verona Pharma, seeing an opportunity to generate more valueNovember 9, 2024 | cnbc.comDavid R. Ebsworth Acquires 39,360 Shares of Verona Pharma plc (NASDAQ:VRNA) StockNovember 8, 2024 | insidertrades.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $64.00November 8, 2024 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $44.00November 8, 2024 | americanbankingnews.comVerona Pharma management to meet with BTIGNovember 7, 2024 | markets.businessinsider.comBrokers Issue Forecasts for Verona Pharma FY2024 EarningsVerona Pharma plc (NASDAQ:VRNA - Free Report) - Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Verona Pharma in a report released on Tuesday, November 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($2.16) per share forNovember 7, 2024 | marketbeat.comHC Wainwright Increases Verona Pharma (NASDAQ:VRNA) Price Target to $42.00November 7, 2024 | americanbankingnews.comRosalind Advisors Inc. Increases Position in Verona Pharma plc (NASDAQ:VRNA)Rosalind Advisors Inc. raised its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 10.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 275,000 shares of the company's stock after acquiring aNovember 6, 2024 | marketbeat.comDavid Zaccardelli Sells 46,888 Shares of Verona Pharma plc (NASDAQ:VRNA) StockNovember 6, 2024 | insidertrades.comLife science firm's $76M expansion to boost volume at Wisconsin plantsNovember 5, 2024 | bizjournals.comRaleigh pharma's stock hits record high amid drug launchNovember 5, 2024 | bizjournals.comBTIG Remains a Buy on Verona Pharma (VRNA)November 5, 2024 | markets.businessinsider.comVerona Pharma plc (NASDAQ:VRNA) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | msn.comVerona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 yearsNovember 5, 2024 | finance.yahoo.comVerona Pharma (NASDAQ:VRNA) Reaches New 1-Year High Following Analyst UpgradeVerona Pharma (NASDAQ:VRNA) Hits New 52-Week High Following Analyst UpgradeNovember 5, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Price Expected to Rise, Wells Fargo & Company Analyst SaysWells Fargo & Company boosted their target price on shares of Verona Pharma from $50.00 to $64.00 and gave the stock an "overweight" rating in a research report on Tuesday.November 5, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Announces Quarterly Earnings ResultsVerona Pharma (NASDAQ:VRNA - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The business had revenue of $5.62 million for the quarter, compared to analysts' expectations of $2.31 million. During the same quarter in the previous year, the business earned ($0.18) earnings per share.November 5, 2024 | marketbeat.comVerona Pharma to Present at Jefferies London Healthcare ConferenceNovember 5, 2024 | globenewswire.comVerona Pharma plc (VRNA) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | seekingalpha.comVerona Pharma (NASDAQ:VRNA) Shares Gap Down - What's Next?Verona Pharma (NASDAQ:VRNA) Shares Gap Down - What's Next?November 4, 2024 | marketbeat.comVerona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 4, 2024 | globenewswire.comVerona Pharma PLC (VRNA) Q3 2024 Earnings Report Preview: What To ExpectNovember 3, 2024 | finance.yahoo.comRice Hall James & Associates LLC Purchases 45,500 Shares of Verona Pharma plc (NASDAQ:VRNA)Rice Hall James & Associates LLC raised its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 4.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 985,076 shares of the company's stock afterNovember 1, 2024 | marketbeat.comVerona Pharma (VRNA) to Release Earnings on MondayVerona Pharma (NASDAQ:VRNA) will be releasing earnings before the market opens on Monday, November 4, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=637673)October 28, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Verona Pharma plc (NASDAQ:VRNA - Get Free Report) have earned a consensus rating of "Buy" from the six brokerages that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target prOctober 28, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 4,800 SharesOctober 26, 2024 | insidertrades.comDavid Zaccardelli Sells 4,800 Shares of Verona Pharma plc (NASDAQ:VRNA) StockVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 4,800 shares of the firm's stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $4.38, for a total transaction of $21,024.00. Following the completion of the transaction, the chief executive officer now directly owns 14,591,736 shares in the company, valued at $63,911,803.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.October 25, 2024 | marketbeat.comZacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona PharmaOctober 25, 2024 | uk.finance.yahoo.comValues First Advisors Inc. Takes $494,000 Position in Verona Pharma plc (NASDAQ:VRNA)Values First Advisors Inc. acquired a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,174 shares of the company's stock, valuedOctober 25, 2024 | marketbeat.comMoody Aldrich Partners LLC Has $7.27 Million Stake in Verona Pharma plc (NASDAQ:VRNA)Moody Aldrich Partners LLC trimmed its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 14.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 252,752 shares of the company's stock after selling 43,193 sOctober 24, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 110,456 SharesOctober 24, 2024 | insidertrades.comInsider Selling: Verona Pharma plc (NASDAQ:VRNA) CEO Sells 110,456 Shares of StockVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 110,456 shares of the stock in a transaction on Monday, October 21st. The stock was sold at an average price of $4.38, for a total value of $483,797.28. Following the sale, the chief executive officer now owns 14,894,464 shares in the company, valued at approximately $65,237,752.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.October 22, 2024 | marketbeat.comVerona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate UpdateOctober 21, 2024 | globenewswire.comVerona Pharma (NASDAQ:VRNA) Hits New 1-Year High - Still a Buy?Verona Pharma (NASDAQ:VRNA) Sets New 12-Month High - Here's WhyOctober 18, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Trading Up 5.7% - Should You Buy?Verona Pharma (NASDAQ:VRNA) Stock Price Up 5.7% - Should You Buy?October 14, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Acquires Shares of 59,418 Verona Pharma plc (NASDAQ:VRNA)The Manufacturers Life Insurance Company acquired a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 59,418 shares of the company's stock, valuOctober 14, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High - What's Next?Verona Pharma (NASDAQ:VRNA) Reaches New 12-Month High - What's Next?October 11, 2024 | marketbeat.comRenaissance Technologies LLC Buys New Stake in Verona Pharma plc (NASDAQ:VRNA)Renaissance Technologies LLC acquired a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 31,044 shares of the company's stock, valued at approximatelyOctober 11, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comMillennium Management LLC Has $7.63 Million Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)Millennium Management LLC lifted its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 4.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 527,640 shares of the company's stock afteOctober 10, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Purchased by Clearbridge Investments LLCClearbridge Investments LLC raised its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 58.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 405,819 shares of the company's stock afterOctober 6, 2024 | marketbeat.comWells Fargo Initiates Coverage of Verona Pharma plc - Depositary Receipt () (VRNA) with Overweight RecommendationOctober 4, 2024 | msn.comVerona Pharma (NASDAQ:VRNA) Sets New 1-Year High - What's Next?Verona Pharma (NASDAQ:VRNA) Reaches New 52-Week High - Should You Buy?October 4, 2024 | marketbeat.comVerona Pharma reiterates stock target, buy rating with positive COPD dataOctober 3, 2024 | investing.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up to $28.71Verona Pharma (NASDAQ:VRNA) Shares Gap Up to $28.71October 3, 2024 | marketbeat.com Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics… Get Your Free Gold Guide VRNA Media Mentions By Week VRNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRNA News Sentiment▼0.610.55▲Average Medical News Sentiment VRNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRNA Articles This Week▼73▲VRNA Articles Average Week Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PCVX News SRPT News CTLT News QGEN News RVMD News ITCI News ROIV News LEGN News LNTH News ASND News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRNA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRNA Stock Alerts